Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)

被引：0
|
作者：
Jansen, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Vernaz-Gris, M. [1 ,2 ,3 ,4 ,5 ,6 ]
DesJardins, C. [1 ,2 ,3 ,4 ,5 ,6 ]
Wong, N. [1 ,2 ,3 ,4 ,5 ,6 ]
Campone, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Cortes, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Wanders, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Shuster, D. [1 ,2 ,3 ,4 ,5 ,6 ]
Fuseau, E. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Eisai Ltd, London, England
[2] EMF Consulting, Aix En Provence, France
[3] Eisai Res Inst, Andover, MA USA
[4] Ctr Rene Gauducheau, St Herblain, France
[5] Vall Hebron Univ Hosp, Barcelona, Spain
[6] Eisai Med Res, Ridgfield Pk, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2524
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Eribulin mesylate in breast cancer
    Verdaguer, Helena
    Morilla, Idoia
    Urruticoechea, Ander
    WOMENS HEALTH, 2013, 9 (06) : 517 - 526
  • [32] Safety and efficacy of eribulin in patients with locally advanced or metastatic breast cancer: A phase IV study in India
    Choudhary, Vaibhav
    Satheesh, C. T.
    Bose, Chinmoy K.
    Rajan, Shiv
    Prakash, Ss
    Desai, Chirag
    Lin, Xiao
    Patil, Balaji
    Chaudhari, Sameer
    Gupta, Sudeep
    ANNALS OF ONCOLOGY, 2022, 33 : S537 - S537
  • [33] Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC)
    Yardley, Denise Aysel
    Osborne, Cynthia R. C.
    Richards, Paul D.
    Daniel, Brooke R.
    Danso, Michael A.
    Favret, Anne
    Bromund, Jane
    Hsu, Yanzhi
    Ibrahim, Ayman B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [34] Anatomical staging and value of CTCs in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC)
    Zhang, Qiang
    Gerratana, Lorenzo
    Flaum, Lisa Flaum
    Shah, Ami Shah
    Davis, Andrew
    Behdad, Amir
    Gradishar, William
    Platanias, Leon
    Cristofanilli, Massimo
    CANCER RESEARCH, 2020, 80 (04)
  • [35] Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer
    Twelves, Chris
    Cortes, Javier
    Vahdat, Linda T.
    Wanders, Jantien
    Akerele, Corina
    Kaufman, Peter A.
    CLINICAL BREAST CANCER, 2010, 10 (02) : 160 - 163
  • [36] Eribulin Mesylate Pharmacokinetics in Patients With Advanced Solid Tumours Receiving Rifampicin
    Devriese, L.
    Witteveen, P. O.
    Marchetti, S.
    Reyderman, L.
    Edwards, G.
    Law, K.
    Wanders, J.
    Beijnen, J.
    Voest, E. E.
    Schellens, J. H. M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S157 - S157
  • [37] Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study
    Barni, S.
    Fontanella, C.
    Del Mastro, L.
    Livraghi, L.
    Morritti, M.
    Pizzuti, L.
    Michelotti, A.
    Lutrino, E. S.
    Ciccarese, M.
    Musolino, A.
    Quercia, S.
    Garrone, O.
    Pellegrino, A.
    Pistelli, M.
    Martella, F.
    Iezzi, L.
    Mentuccia, L.
    Latorre, A.
    D'Onofrio, L.
    Porcu, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S282
  • [38] Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study
    Cortes, Javier
    Awada, Ahmad
    Kaufman, Peter Andrew
    Yelle, Louise
    Perez, Edith A.
    Velikova, Galina
    Wanders, Jantien
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina
    Simons, W. Robert
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Eribulin use in MBC (Metastatic breast cancer) in resource limited setting
    Roy, Rakesh
    Sarkar, Abhijit
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer
    Schmidt, M.
    Jackisch, C.
    Hesse, T.
    Hoffmann, O.
    Heinrich, B. J.
    Park-Simon, T-W
    Grischke, E-M.
    Weide, R.
    Mueller-Huesmann, H.
    Welslau, M.
    Wu, J.
    Schmitz, H.
    Engelbrecht, C.
    Lueck, H-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S496 - S497
12345